OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost Buys 199,072 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 199,072 shares of the business’s stock in a transaction on Friday, November 29th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $304,580.16. Following the completion of the acquisition, the chief executive officer now directly owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. The trade was a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost bought 280,183 shares of OPKO Health stock. The shares were acquired at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Trading Down 2.5 %

Shares of OPK opened at $1.54 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The firm has a market cap of $1.05 billion, a P/E ratio of -8.11 and a beta of 1.65. OPKO Health, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $1.75. The business has a 50-day moving average of $1.51 and a 200 day moving average of $1.45.

Institutional Trading of OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of the business. Rubric Capital Management LP lifted its position in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares in the last quarter. Assenagon Asset Management S.A. boosted its position in shares of OPKO Health by 142.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock valued at $2,227,000 after acquiring an additional 876,272 shares during the period. Squarepoint Ops LLC purchased a new position in OPKO Health during the second quarter valued at approximately $592,000. Tidal Investments LLC bought a new stake in OPKO Health during the 1st quarter worth approximately $239,000. Finally, Y.D. More Investments Ltd purchased a new stake in OPKO Health in the 2nd quarter worth approximately $1,840,000. Institutional investors own 64.63% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $3.00 price target on shares of OPKO Health in a research report on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, November 8th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.